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Abstract: Hereditary hemochromatosis (HH) is a disorder of iron accumulation in tissues, which is related to coronary 
heart diseases. Free radicals and reactive oxygen species, created because of iron deposition, promote oxidation of LDL 
cholesterol and could lead to the development of atherosclerosis. Studies have shown that HFE gene mutation carriers 
might be at higher risk of developing cardiovascular diseases compared with non-carriers. 
This study aimed to determine the frequency of HFE gene mutations in patients with myocardial infarction compared 
to a healthy group in eastern Slavonia. 
A retrospective case-control study was carried out on a population of 400 participants. In the first group there were 200 
patients (114 males and 86 females) with myocardial infarction. The second group consisted of 200 controls (103 males 
and 97 females) without a history of cardiovascular diseases.  
All patients were genotyped for the three most common mutations of the HH in the HFE gene: C282Y, H63D, and 
S65C, by real-time PCR. The difference in the frequency of carriers of these mutations between the patients and the 
controls was not significant (C282Y: 4.5 vs. 8.1%; H63D: 19 vs. 24.5%; S65C: 3.5 versus 4%), and neither was the 
frequency and distribution of possible HFE gene genotypes and compound heterozygotes. There were no statistically 
significant associations of cardiovascular risk factors and HFE gene mutations in patients with myocardial infarction. 
In this study, no association was found between the HFE gene mutation for HH and myocardial infarction in the 
population of eastern Slavonia.  
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Hereditary hemochromatosis (HH) is an autosomal 
recessive disorder of iron metabolism marked by 
increased absorption and accumulation of iron in the 
parenchymal cells of the liver, pancreas, heart and 
some endocrine organs, which may lead to tissue injury 
and dysfunction.
1, 2
 Based on clinical, biochemical, and 
genetic characteristics, five types of HH have been 
identified. The most common mutation is in the HFE 
gene on chromosome 6p21.3, and it is classic 
hemochromatosis (type 1).
2
 In addition to the HFE 
gene, mutations in the genes that encode hemojuvelin 
(HJV, type 2A), hepcidin (HAMP, type 2B), transferrin 
receptor 2 (TFR2, type 3) and ferroportin (SLC40A1, 
type 4) have been associated with the regulation of iron 
homeostasis and the development of HH.
2, 3
 If the 
transferrin saturation is higher than 45%, and ferritin 
exceeds local reference ranges, HFE mutations should 
be investigated.
4, 5
   
The hemochromatosis HFE gene was discovered in 
1996. The HFE gene encodes the major 
histocompatibility complex (MHC) class I-like protein 
HFE that binds β2-microglobulin. HFE influences iron 
absorption by modulating the expression of hepcidin, 
the primary regulator of iron metabolism.
6, 7
 In the 
same year, 1996, two base-pair alterations of the HFE 
gene, termed C282Y and H63D, were identified in 
hereditary hemochromatosis.
8
 The first was the 
missense mutation at position 282, where cysteine is 
replaced by tyrosine (p.Cys282Tyr, c.845G>A), the 
second mutation is the substitution of histidine for 
aspartic acid at position 63 (p.His63Asp, c.187C>G), 
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the third mutation is the substitution of cysteine for 
serine (p.Ser65Cys, c.193A>T).
2
 Table 1 presents the 
data for the genotype frequency of the three most 
common mutations of the HFE gene with a clinical 
manifestation on iron status. 
The penetrance of disease in C282Y homozygotes is 
incomplete,
9
 and for C282Y homozygosity is 13.5%.
10
 
Penetrance is higher in males between 40 and 60 years 
of age than in female C282Y homozygotes (28% vs. 
1%). 25–35% of C282Y homozygous individuals 
develop the disease.
9, 11
 Only 1-2% of compound 
heterozygotes C282Y/H63D have a predisposition to 
develop the disease.
12
 It is considered that 
homozygosity for H63D is not a sufficient genetic 
cause of iron overload, while S65C mutation may 
contribute to mild iron overload, with no clinical 
expression only when inherited in trans with the 
C282Y mutation.
10




The proposed mechanism for explaining HH was the 
disruption of a disulfide bond in the HFE protein that is 
critical for its binding to β2-microglobulin. The 
functional loss of HFE in humans has been shown to 
reduce hepcidin synthesis.
2, 14
 The C282Y mutation 
disrupts a critical disulfide bond in the α3 domain of 
HFE, destroying the β2-microglobulin binding capacity 
of HFE and limiting its localization to the cytoplasm. 
All this leads to iron overload by decreasing the hepatic 
synthesis of hepcidin.
6, 15, 16
 Mutations H63D and S65C 
affect the α1 binding groove, but do not prevent HFE 
presentation on cell surfaces.
6
  
Iron-dependent cardiovascular disease risk might be 
related to increased oxidative stress and endothelial 
dysfunction.
1
 An increased body iron store has been 
shown to be an independent risk factor for myocardial 
infarction (MI).
1, 17
 Iron could promote the formation of 
reactive oxygen species and enhance lipid 
peroxidation, an essential step in atherosclerosis and 
myocardial infarction.
1, 18, 19
 Oxygen free radicals 
presumably damage cells by oxidating various cellular 
components, and promote the damage that occurs 
during ischemia and reperfusion.
19, 20
 Studies have 
shown that HFE gene mutation carriers might be at 




This study aimed to determine the prevalence of HFE 
gene mutations in hereditary hemochromatosis among 
patients who had survived the myocardial infarction 
compared to a healthy group in eastern Slavonia.  
 
 
MATERIAL AND METHODS 
The study was conducted on patients with myocardial 
infarction at the Clinical Department of Cardiovascular 
Diseases and Intensive Care at the University Hospital 
Osijek, Croatia.  
Thygesen et al. defined MI by the presence of at least 
two of the following: typical increase in the 
biochemical marker of myocardial necrosis - cardiac 
troponin T (above the 99
th
 percentile), ischemic chest 
pain symptoms lasting for more than 30 minutes, and 
electrocardiography (ECG) changes indicative of 
ischemia (ST-segment elevation or depression).
21
  
Systematic information on the past and present medical 
history was collected from all participants. Body mass 
index (BMI) was calculated as weight in kilograms 
divided by square of height in meters. Smokers were 
participants who currently smoked. All data given were 
checked in the patients’ medical records. 
Two hundred healthy sex- and age-matched 
participants were included in the control group. Their 
medical documentation did not show any history of 
cardiovascular diseases. The study was carried out 
according to the Declaration of Helsinki and its 
amendments. Written informed consent was obtained 
from all participants in the study. 
In this study, the three most common mutations in the 
HFE gene were genotyped: Cys282Tyr (C282Y, 
845G>A), His63Asp (H63D, 187C>G), and Ser65Cys 
(S65C, 193A>T).  
Genomic DNA was obtained from peripheral blood 
lymphocytes using a QIAamp DNA Blood Mini Kit, 
Qiagen, Hilden, Germany. Mutation genotyping was 
conducted by the real-time PCR method performed on 
the 7500 Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA) applying TaqMan SNP 
genotyping assays. The mutation analysis was done 
using SDS 7500 Software Version 2.3 (Applied 
Biosystems, Foster City, CA, USA).  
Data were expressed as absolute frequencies with 
percentages or means with standard deviations (SD). 
The association between the genotypes and 
cardiovascular risk factors  were tested using  one-way 
 
 
Table 1. Genotype frequency of the three most common HFE gene mutations 
Genotype Frequency Disease manifestation 
C282Y homozygote 90% From no evidence to massive iron overload 
C282Y/H63D compound heterozygote 5% Mild to moderate iron overload 
C282Y heterozygote 10% Normal iron status 
H63D homozygote 1% Mild to moderate iron overload 
H63D heterozygote 20% Normal iron status 
S65C homozygote 0.5% Normal iron status or mild iron overload 
C282Y/S65C compound heterozygote <0.5% Normal iron status or mild iron overload 
S65C heterozygote 1-2% Normal iron status 
H63D/S65C compound heterozygote <0.5% Normal iron status or mild iron overload 
no HFE mutation <0.001% Iron overload associated with mutations in other genes 
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analysis of variance (ANOVA), the Mann-Whitney U 
test, and Kruskal-Wallis test. Chi-square tests (χ2) on 
contingency tables were applied to compare allelic and 
genotype frequencies in controls and cases. The level 
of statistical significance was set at P<0.05 and all 
significant values were assessed after correction for the 
number of independent hypotheses tested. All analyses 
were adjusted by age and performed using Statistica 12 





The prevalence of cardiovascular risk factors among all 
participants included in the study sample is 
summarized in Table 2. The mean age of the study 
population was 64±13 years, and 54.5% were males. A 
significant difference between two groups was found 
for hypertension and smoking. The association of the 
cardiovascular risk factors and HFE gene mutations in 
MI patients is shown in Table 3.  
 
 
Table 2. Prevalence of cardiovascular risk factors among all 







Age year mean 
(SD) 
66±12  62±13 0.086 
Gender (males) 114 (57%) 104 (52%) 0.317 
BMI* (kg/m2) 28.7±4.7 26.9±4.3 0.327 
Smokers  41 (20.5%) 39 (19.5%) <0.001 
Hypertension 107 (53.5%) 59 (29.5%) <0.001 
Dyslipidemia 26 (13%) 23 (11.5%) 0.648 
Respiratory disease 2 (1.8%) 8 (4%) 0.055 
Diabetes mellitus 2 44 (22%) 0 - 
Kidney diseases 15 (7.5%) 12 (6%) 0.550 
Liver disease 10 (5%) 9 (4.5%) 0.814 
*BMI - body mass index; Numerical variables are presented as mean 
(SD), while categorical variables as number (percentage). 
 
 
Table 3. The association of cardiovascular risk factors and HFE 
gene mutations in MI patients 
Variables C282Y H63D S65C 
Age*  0.919 0.829 0.291 
Gender  0.437 NA 0.434 
BMI* 0.850 0.807 0.773 
Smoking 0.373 0.221 0.489 
Hypertension  0.055 0.923 0.179 
Dyslipidemia 0.863 0.829 0.918 
Respiratory diseases 0.758 0.463 0.787 
Diabetes mellitus 2 0.987 0.620 0.176 
Thyroid gland diseases 0.266 0.537 0.583 
Kidney diseases 0.383 0.155 0.489 
Liver diseases 0.482 0.405 0.538 
Mann-Whitney U test P-value; * Kruskal-Wallis test P-value; BMI – 
body mass index; NA - not applicable 
We did not find any association between the HFE gene 
mutations and previous MI. The frequency of carriers 
of mutations between MI patients and controls was not 
significant (C282Y: 4.5 vs. 8.1%; H63D: 19 vs. 24.5%; 
S65C: 3.5 versus 4%), and neither was the frequency 









Genotype frequency (%) 
P 
MI patients Controls 
C282Y 
GG 95.5 92.0 
0.148 AG 4.5 8.0 
AA - - 
H63D 
CC 79.0 74.0 
0.394 CG 19.0 24.5 
GG 2.0 1.5 
S65C 
AA 96.5 96.0 
0.779 AT 3.5 4.0 
TT - - 
 
The H63D mutation was the most common mutation of 
the three HFE gene mutations studied (Table 4). None 
of the participants were homozygotes for the C282Y 
mutation or the S65C mutation. 
Among the nine C282Y heterozygous MI patients, 
there was one C282Y/H63D compound heterozygote. 
However, one C282Y/H63D compound heterozygote 
was also detected among the controls. Three 
H63D/S65C compound heterozygotes were found in 
the control group (Table 5). 
 
 
Table 5. The prevalence of compound heterozygotes in the 
studied population 
Compound heterozygote MI patients (%) Controls (%) 
C282Y/H63D 0.5 0.5 
C282Y/S65C 0 0 




There is no evidence for a higher prevalence of the 
HFE gene mutation in MI patients. The number of 
homozygotes was too small for statistical analysis. 
There was no significant association between a history 
of MI and mutations in the HFE gene, and our 
participants did not suffer from clinical HH. Also, there 
were no statistically significant associations of the 11 
covariates and HFE gene mutations in patients with 
myocardial infarction (Table 3).  
The most common mutation among our participants 
was H63D, which is similar to research done by Claeys 
and coworkers.
1
 They showed that the H63D mutation 
is more common than the C282Y mutation in patients 
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with a history of cardiovascular diseases (26.5 vs. 
12.4%),1 but the exact mechanism which would lead to 
HH is unknown.  
Many studies have found an association of the C282CY 
mutation with an increased risk of myocardial 
infarction and coronary heart disease.
16, 18, 22
 These 
studies suggest that the HFE gene mutation, especially 
C282Y, might promote cardiovascular diseases. Body 
iron status is involved in atherosclerotic cardiovascular 
disease. High iron status is linked with increased 
oxidation of LDL.
10, 23
 Cells are shielded against iron-
induced oxidative destruction by the generation of 
ferritin. The first study of the association between 
serum ferritin and cardiovascular diseases was done by 
Salonen et al.
24
 The association between serum ferritin 
and risk for cardiovascular diseases has been 
investigated in 20 different studies. However, only in 3 
of those studies a statistically significant association 
was found between ferritin levels and cardiovascular 
diseases.
25
 A possible explanation is that heterozygotes 
are relatively common (15-20%), so heterozygotes 
would form a substantial pool of persons at increased 
risk for cardiovascular diseases.
25
 In male Iranian 
cardiovascular patients, increased ferritin might be an 
independent predictor of MI.
23
 Cardiac myocytes, like 
hepatocytes, have a high affinity for non-transferrin 
bound iron. In the heart, an iron overload occurs 
mainly in the ventricles, where it induces fibrosis and 
alteration of myocardial fibers. As iron overload 
severity increases, diastolic dysfunction of the left 
ventricle occurs, followed by impaired systolic 
dysfunction.
3
 In the study by Gaenzer et al., it was 
shown that endothelial function is impaired in patients 
with hemochromatosis and profound iron overload, 




Carpenter et al. showed that dilated cardiomyopathy is 
associated with an increased frequency of the H63D 
mutation, but not the C282Y mutation. The H63D 
mutation has less effect on iron metabolism compared 
with C282Y.
27
 The most common mutation among our 
participants was H63D. A higher prevalence of the 
H63D mutation was observed among MI patients than 
controls (2 vs. 1.5%). The frequency of the H63D 
mutation is higher than the C282Y mutation in 
populations of north-western European origin (40 vs. 
20%).
1
 Steinberg et al. found that the H63D mutation is 
more common in white individuals in the USA (15-
40%) than C282Y. The prevalence of the C282Y 
mutation is estimated to be 5.4%, while the H63D 
mutation is seen in 13.5% of the total US population.
28
 
The H63D mutation is cosmopolitan, but its frequency 
is highest in whites of European descent, although the 




Differences in levels of stored iron could explain the 
difference in the incidence of heart disease between 
men and women.
19
 Men eat more red meat and have a 
higher intake of heme, which could lead to an increased 
risk of myocardial infarction, while exercise is 
associated with reduced mortality from cardiovascular 
disease.
19
 A positive association of the HFE gene 
mutation and a higher risk from cardiovascular disease 
was found in women.
22
 However, women have a lower 
incidence of coronary artery disease due to lower iron 
levels from menstruation, and increased incidence of 
cardiovascular diseases.
27
 Male carriers of the C282Y 
mutation are at a higher risk from first myocardial 
infarction compared with non-carriers.
16
 De-ironing 
therapy might prevent the potential tissue damage, such 
as cardiomyopathy of iron overload, by phlebotomy.
4, 
29 
The effect of hemochromatosis on cardiovascular 
disease incidence is most pronounced in younger 
individuals.
16
 If we assume that iron plays an important 
role in cardiovascular diseases, other genetic factors 
that determine iron status may lead to confusion or 
reduce the risk of hemochromatosis in specific 
populations. This problem might become more 
important when research involves elderly participants 
who usually have more iron replete.
1
 In this study, the 
average age of participants was 65, and it is possible 
that the observed prevalence rate of homozygous and, 
perhaps of heterozygous, for the HFE mutations is 
underestimated due to survival bias.
16
  
The majority of prospective studies have not shown the 
association of serum ferritin or other iron 
measurements with cardiovascular disease.
30
 The 
effects of HFE on serum ferritin are lower compared to 
effects on serum iron and the saturation of serum 
transferrin with iron. Other unknown genes have an 
effect on iron stores that are considerably higher than 
those of HFE.
31
 Differences in study designs and ethnic 
backgrounds, with different gene to gene or genes with 
the environment interactions, might be reasonable 
explanations for the opposite results. Genetic 
polymorphisms on other locus and non-genetic 
differences probably play a significant role in 
determining the iron status. If iron is involved, other 
factors can easily lead to confusion about the 
association between cardiovascular risk and 
heterozygosity of the HFE mutation in different 
studies.
30
 The HFE gene is located in a gene-rich 
region where the most important is the HLA gene. The 
increased risk for MI could be modified by mutations 
of some other genes that are not related to iron 
metabolism but are coinherited with HFE gene 
mutations.
16
 Finally, in the HLA gene region there are 




We should consider some limitations of the study. The 
sample size is relatively small and included patients 
who had survived MI. Our sample had the advantage of 
being relatively homogenous for demographic 
variables such as age, ethnicity, and social 
environment, as well as cardiovascular risk factors. The 
first bias is selective mortality; only MI survivors are 
included. Surviving MI patients had endothelial 
dysfunction and/or atherosclerosis. The second bias is 
that serum ferritin levels were not measured as the 
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biochemical marker for HH, but it is known that ferritin 
levels in blood increase after MI. Another limitation of 
the study was lack of the measurement of the 
biomarkers of oxidative stress. 
In conclusion, the C282Y, H63D, and S65C mutations 
in the HFE gene did not enhance the risk of MI in our 
patients with a history of myocardial infarction. The 
most exciting finding is that the most common 
mutation in this study was H63D. Our results, showing 
that predisposition to MI is not linked to HFE 
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